Tug of War between Survival and Death: Exploring ATM Function in Cancer
Abstract
:1. Introduction
2. Role of Ataxia-Telangiectasia Mutated (ATM) Deficiency in Mouse Models
3. ATM Expression or Activity and Human Cancer
4. ATM and the DNA Damage Response (DDR) Activation by Oncogene Stress: Is This Only a Barrier to Cancer Development?
5. ATM Dependent Modulation of Signaling Pathways Outside DDR Implicated in Cancer
5.1. ATM and Death Receptor Induced Apoptosis
5.2. ATM and Receptor Tyrosine Kinases
5.3. ATM and Oxidative Stress
5.4. ATM, Hypoxia and Angiogenesis
5.5. ATM Activity Modulates Stem Cell Survival and Proliferation
6. Modulation of ATM Activity in Cancer Therapy
7. Concluding Remarks
Acknowledgments
Conflicts of Interest
- Author ContributionsD.B. and V.S. conceived the article structure; D.B. wrote, edited and assembled the manuscript; V.S. and M.A. contributed to write Section 4.5 and 5.; V.O. contributed to write Section 4.2, 4.3, and 5; G.F. contributed to write Section 4.1, 4.4 and 5; I.C. contributed to write Section 4.5.
References
- Shiloh, Y. Atm and related protein kinases: Safeguarding genome integrity. Nat. Rev. Cancer 2003, 3, 155–167. [Google Scholar]
- Bakkenist, C.J.; Kastan, M.B. Initiating cellular stress responses. Cell 2004, 118, 9–17. [Google Scholar]
- Lavin, M.F. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat. Rev. Mol. Cell Biol 2008, 9, 759–769. [Google Scholar]
- Bhatti, S.; Kozlov, S.; Farooqi, A.A.; Naqui, A.; Lavin, M.F.; Khanna, K.K. Atm protein kinase: The linchpin of cellular defenses to stress. Cell. Mol. Life Sci 2011, 68, 2977–3006. [Google Scholar]
- McKinnon, P.J. Atm and the molecular pathogenesis of ataxia-telangiectasia. Annu. Rev. Pathol 2012, 7, 303–321. [Google Scholar]
- Herrup, K.; Li, J.; Chen, J. The role of Atm and DNA damage in neurons: Upstream and downstream connections. DNA Repair 2013, 12, 600–604. [Google Scholar]
- Shiloh, Y.; Ziv, Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol 2013, 14, 197–210. [Google Scholar]
- Stracker, T.H.; Roig, I.; Knobel, P.A.; Marjanović, M. The ATM signaling network in development and disease. Front. Genet 2013. [Google Scholar]
- Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421, 499–506. [Google Scholar]
- Pellegrini, M.; Celeste, A.; Difilippantonio, S.; Guo, R.; Wang, W.; Feigenbaum, L.; Nussenzweig, A. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 2006, 443, 222–225. [Google Scholar]
- Daniel, J.A.; Pellegrini, M.; Lee, J.H.; Paull, T.T.; Feigenbaum, L.; Nussenzweig, A. Multiple autophosphorylation sites are dispensable for murine Atm activation in vivo. J. Cell Biol. 2008, 183, 777–783. [Google Scholar]
- Uziel, T.; Lerenthal, Y.; Moyal, L.; Andegeko, Y.; Mittelman, L.; Shiloh, Y. Requirement of the MRN complex for Atm activation by DNA damage. EMBO J 2003, 22, 5612–5621. [Google Scholar]
- Lee, J.H.; Paull, T.T. Atm activation by DNA double-strand breaks through the mre11–rad50–nbs1 complex. Science 2005, 308, 551–554. [Google Scholar]
- Barlow, C.; Hirotsune, S.; Paylor, R.; Liyanage, M.; Eckhaus, M.; Collins, F.; Shiloh, Y.; Crawley, J.N.; Ried, T.; Tagle, D.; et al. Atm-deficient mice: A paradigm of ataxia-telangiectasia. Cell 1996, 86, 159–171. [Google Scholar]
- Xu, Y.; Ashley, T.; Brainerd, E.; Bronson, R.T.; Meyn, M.S.; Baltimore, D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 1996, 10, 2411–2422. [Google Scholar]
- Elson, A.; Wang, Y.; Daugherty, C.J.; Morton, C.C.; Zhou, F.; Campos-Torres, J.; Leder, P. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. USA 1996, 93, 13084–13089. [Google Scholar]
- Daniel, J.A.; Pellegrini, M.; Lee, B.S.; Guo, Z.; Filsuf, D.; Belkina, N.V.; You, Z.; Paull, T.T.; Sleckman, B.P.; Feigenbaum, L.; et al. Loss of ATM kinase activity leads to embryonic lethality in mice. J. Cell Biol 2012, 198, 295–304. [Google Scholar]
- Yamamoto, K.; Wang, Y.; Jiang, W.; Liu, X.; Dubois, R.L.; Lin, C.S.; Ludwig, T.; Bakkenist, C.J.; Zha, S. Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice. J. Cell Biol 2012, 198, 305–313. [Google Scholar]
- Kwong, L.N.; Weiss, K.R.; Haigis, K.M.; Dove, W.F. ATM is a negative regulator of intestinal neoplasia. Oncogene 2008, 27, 1013–1018. [Google Scholar]
- Pusapati, R.V.; Rounbehler, R.J.; Hong, S.S.; Powers, J.T.; Yan, M.; Kiguchi, K.; McArthur, M.J.; Wong, P.K.; Johnson, D.G. ATM promotes apoptosis and suppresses tumorigenesis in response toMyc. Proc. Natl. Acad. Sci. USA 2006, 103, 1446–1451. [Google Scholar]
- Maclean, K.H.; Kastan, M.B.; Cleveland, J.L. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol. Cancer Res 2007, 5, 705–711. [Google Scholar]
- Umesako, S.; Fujisawa, K.; Iiga, S.; Mori, N.; Takahashi, M.; Hong, D.P.; Song, C.W.; Haga, S.; Imai, S.; Niwa, O.; et al. Atm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice. Breast Cancer Res 2005, 7, R164–R170. [Google Scholar]
- Gumy-Pause, F.; Wacker, P.; Sappino, A.P. Atm gene and lymphoid malignancies. Leukemia 2004, 18, 238–242. [Google Scholar]
- Matei, I.R.; Guidos, C.J.; Danska, J.S. Atm-dependent DNA damage surveillance in T-cell development and leukemogenesis: The DSB connection. Immunol. Rev 2006, 209, 142–158. [Google Scholar]
- Krammer, P.H. Cd95’s deadly mission in the immune system. Nature 2000, 407, 789–795. [Google Scholar]
- Stagni, V.; di Bari, M.G.; Condò, I.; Cursi, S.; Testi, R.; Larenthal, Y.; Cundari, E.; Barilà, D. ATM kinase activity modulates Fas sensitivity through the regulation of flip in lymphoid cells. Blood 2008, 111, 829–837. [Google Scholar]
- Stagni, V.; Mingardi, M.; Santini, S.; Giaccari, D.; Barilà, D. ATM kinase activity modulates cflip protein levels: Potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 2010, 31, 1956–1963. [Google Scholar]
- Renwick, A.; Thompson, D.; Seal, S.; Kelly, P.; Chagtai, T.; Ahmed, M.; North, B.; Jayatilake, H.; Barfoot, R.; Spanova, K.; et al. Atm mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet 2006, 38, 873–875. [Google Scholar]
- Goldgar, D.E.; Healey, S.; Dowty, J.G.; da Silva, L.; Chen, X.; Spurdle, A.B.; Terry, M.B.; Daly, M.J.; Buys, S.M.; Southey, M.C.; et al. Rare variants in the Atm gene and risk of breast cancer. Breast Cancer Res 2011, 13, R73:1–R73:9. [Google Scholar]
- Roberts, N.J.; Jiao, Y.; Yu, J.P.; Kopelovich, L.; Petersen, G.M.; Bondy, M.L.; Gallinger, S.; Schwartz, A.G.; Syngal, S.; Cote, M.L.; et al. Atm mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012, 2, 41–46. [Google Scholar]
- Guarini, A.; Marinelli, M.; Tavolaro, S.; Bellacchio, E.; Magliozzi, M.; Chiaretti, S.; de Propris, M.S.; Peragine, N.; Santangelo, S.; Paoloni, F.; et al. Atm gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 2012, 97, 47–55. [Google Scholar]
- Cremona, C.A.; Behrens, A. Atm signalling and cancer. Oncogene 2013. [Google Scholar] [CrossRef]
- Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486, 346–352. [Google Scholar]
- The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature 2012, 490, 61–70.
- Ding, L.; Getz, G.; Wheeler, D.A.; Mardis, E.R.; McLellan, M.D.; Cibulskis, K.; Sougnez, C.; Greulich, H.; Muzny, D.M.; Morgan, M.B.; et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455, 1069–1075. [Google Scholar]
- Seshagiri, S.; Stawiski, E.W.; Durinck, S.; Modrusan, Z.; Storm, E.E.; Conboy, C.B.; Chaudhuri, S.; Guan, Y.; Janakiraman, V.; Jaiswal, B.S.; et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488, 660–664. [Google Scholar]
- Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Ziegert, K.; Guldeberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434, 864–870. [Google Scholar]
- Gorgoulis, V.G.; Vassiliou, L.V.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; Ditullio, R.A.J.; Kastrinakis, N.G.; Levy, B.; et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434, 907–913. [Google Scholar]
- Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L.V.; Kolettas, E.; Niforou, K.; Zoumpourlis, V.C.; et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444, 633–637. [Google Scholar]
- Di Micco, R.; Fumagalli, M.; Cicalese, A.; Piccinin, S.; Gasparini, P.; Luise, C.; Schurra, C.; Garre’, M.; Nuciforo, P.G.; Bensimon, A.; et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444, 638–642. [Google Scholar]
- Mallette, F.A.; Gaumont-Leclerc, M.F.; Ferbeyre, G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007, 21, 43–48. [Google Scholar]
- Bartek, J.; Bartkova, J.; Lukas, J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26, 7773–7779. [Google Scholar]
- Frame, F.M.; Rogoff, H.A.; Pickering, M.T.; Cress, W.D.; Kowalik, T.F. E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. Oncogene 2006, 25, 3258–3266. [Google Scholar]
- Pickering, M.T.; Kowalik, T.F. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 2006, 25, 746–755. [Google Scholar]
- Reddy, J.P.; Peddibhotia, S.; Bu, W.; Zhao, J.; Haricharan, S.; Du, Y.-C.N.; Podsypanina, K.; Rosen, J.M.; Donehower, L.A.; Li, Y. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc. Natl. Acad. Sci. USA 2010, 107, 3728–3733. [Google Scholar]
- Tort, F.; Bartkova, J.; Sehested, M.; Orntoft, T.; Lukas, J.; Bartek, J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 2006, 66, 10258–10263. [Google Scholar]
- Gorrini, C.; Squatrito, M.; Luise, C.; Syed, N.; Perna, D.; Wark, L.; Martinato, F.; Sardella, D.; Verrecchia, A.; Bennett, S.; et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007, 448, 1063–1067. [Google Scholar]
- Squatrito, M.; Brennan, C.W.; Helmy, K.; Huse, J.T.; Petrini, J.H.; Holland, E.C. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010, 18, 619–629. [Google Scholar]
- Takacova, S.; Slany, R.; Bartkova, J.; Stranecky, V.; Dolezel, P.; Luzna, P.; Bartek, J.; Divoky, V. DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesisin vivo. Cancer Cell 2012, 21, 517–531. [Google Scholar]
- Gupta, G.P.; Vanness, K.; Barlas, A.; Manova-Todorova, K.O.; Wen, Y.H.; Petrini, J.H. The Mre11 complex suppresses oncogene-driven breast tumorigenesis and metastasis. Mol. Cell 2013, 52, 353–365. [Google Scholar]
- Golomb, L.; Oren, M. In the race for protection, ARF comes second. Cell Death Differ 2013, 20, 1442–1443. [Google Scholar]
- Velimezi, G.; Liontos, M.; Vougas, K.; Roumeliotis, T.; Bartkova, J.; Sideridou, M.; Dereli-Oz, A.; Kocylowski, M.; Pateras, I.S.; Evangelou, K.; et al. Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat. Cell Biol 2013, 15, 967–977. [Google Scholar]
- Evangelou, K.; Bartkova, J.; Kotsinas, A.; Pateras, I.S.; Liontos, M.; Velimezi, G.; Kosar, M.; Liloglou, T.; Trougakos, I.P.; Dyrskjot, L.; et al. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ 2013, 20, 1485–1497. [Google Scholar]
- Matsuoka, S.; Ballif, B.; Smogorzewska, A.; McDonald, E.R.; Hurov, K.; Luo, J.L.; Bakalarski, C.; Zhao, Z.; Solimini, N.; Lerenthal, Y.; et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316, 1160–1166. [Google Scholar]
- Mu, J.-J.; Wang, Y.; Luo, H.; Leng, M.; Zhang, J.; Yang, T.; Besusso, D.; Jung, S.Y.; Qin, J. A proteomic analysis of ataxia-telangiectasia mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints. J. Biol. Chem 2007, 282, 17330–17334. [Google Scholar]
- Lim, D.S.; Kirsch, D.G.; Canman, C.E.; Ahn, J.H.; Ziv, Y.; Newman, L.S.; Darnell, R.B.; Shiloh, Y.; Kastan, M.B. ATM binds to β-adaptin in cytoplasmic vesicles. Proc. Natl. Acad. Sci. USA 1998, 95, 10146–10151. [Google Scholar]
- Barlow, C.; Ribaut-Barassin, C.; Zwingman, T.A.; Pope, A.J.; Brown, K.D.; Owens, J.W.; Larson, D.; Harrington, E.A.; Haeberle, A.M.; Mariani, J.; et al. ATM is a cytoplasmic protein in mouse brain required to prevent lysosomal accumulation. Proc. Natl. Acad. Sci. USA 2000, 97, 871–876. [Google Scholar]
- Boehrs, J.K.; He, J.; Halaby, M.J.; Yang, D.Q. Constitutive expression and cytoplasmic compartmentalization of ATM protein in differentiated human neuron-like SH-SY5Y cells. J. Neurochem 2007, 100, 337–345. [Google Scholar]
- Li, J.; Han, Y.R.; Plummer, M.R.; Herrup, K. Cytoplasmic ATM in neurons modulates synaptic function. Curr. Biol 2009, 19, 2091–2096. [Google Scholar]
- Valentin-Vega, Y.A.; MacLean, K.H.; Tait-Mulder, J.; Milasta, S.; Steeves, M.; Dorsey, F.C.; Cleveland, J.L.; Green, D.R.; Kastan, M.B. Mitochondrial dysfunction in ataxia-telangiectasia. Blood 2012, 119, 1490–1500. [Google Scholar]
- MacFarlane, M. TRAIL-induced signalling and apoptosis. Toxicol. Lett 2003, 139, 89–97. [Google Scholar]
- Falschlehner, C.; Emmerich, C.H.; Gerlach, B.; Walczak, H. TRAIL signalling: Decisions between life and death. Int. J. Biochem. Cell Biol 2007, 39, 1462–1475. [Google Scholar]
- Yu, J.W.; Shi, Y. Flip and death effector domain family. Oncogene 2008, 27, 6216–6227. [Google Scholar]
- Stagni, V.; Santini, S.; Barilà, D. Molecular bases of ataxia-telangiectasia: One kinase multiple functions. Genetic Disorders; InTech: Rijeka, Croatia, 2013. Available online: http://www.intechopen.com/books/genetic-disorders/molecular-bases-of-ataxia-telangiectasia-onekinase-multiple-functions (accessed on 9 January 2013).
- Santini, S.; Stagni, V.; Giambruno, R.; Fianco, G.; di Benedetto, A.; Mottolese, M.; Pellegrini, M.; Barilà, D. ATM kinase activity modulates ITCH E3-ubiquitin ligase activity. Oncogene 2014, 33, 1113–1123. [Google Scholar]
- Safa, A.R.; Pollok, K.E. Targeting the anti-apoptotic protein C-FLIP for cancer therapy. Cancers 2011, 3, 1639–1671. [Google Scholar]
- Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134. [Google Scholar]
- Bar, R.S.; Levis, W.R.; Rechler, M.M.; Harrison, L.C.; Siebert, C.; Podskalny, J.; Roth, J.; Muggeo, M. Extreme insulin resistance in ataxia-telangiectasia: Defect in affinity of insulin receptors. N. Engl. J. Med 1978, 298, 1164–1171. [Google Scholar]
- Yang, D.-Q.; Kastan, M.B. Partecipation of ATM in insulin signalling through phosphorylation of eIF-4E-binding protein 1. Nat. Cell Biol 2000, 2, 893–898. [Google Scholar]
- Halaby, M.J.; Hibma, J.C.; He, J.; Yang, D.Q. ATM protein kinase mediates full activation of AKT and regulates glucose transporter 4 translocation by insulin in muscle cells. Cell. Signal 2008, 20, 1555–1563. [Google Scholar]
- Schneider, J.G.; Finck, B.N.; Ren, J.; Standley, K.N.; Takagi, M.; MacLean, K.H.; Bernal-Mizrachi, C.; Muslin, A.J.; Kastan, M.B.; Semenkovich, C.F. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006, 4, 377–389. [Google Scholar]
- Manning, B.D.; Cantley, L.C. AKT/PKB signaling: Navigating downstream. Cell 2007, 129, 1261–1274. [Google Scholar]
- Cho, H.; Mu, J.; Kim, J.K.; Thorvaldsen, J.L.; Chu, Q.; Crenshaw, E.B.; Kaestner, K.H.; Bartolomei, M.S.; Shulman, G.I.; Birnbaum, M.J. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase AKT2 (PKB β). Science 2001, 292, 1728–1731. [Google Scholar]
- Viniegra, J.G.; Martínez, N.; Modirassari, P.; Hernández Losa, J.; Parada Cobo, C.; Sánchez-Arévalo Lobo, V.J.; Aceves Luquero, C.I.; Alvarez-Vallina, L.; Ramón y Cajal, S.; Rojas, J.M.; et al. Full activation of PKB/AKT in response to insulin or ionizing radiation is mediated through ATM. J. Biol. Chem 2005, 280, 4029–4036. [Google Scholar]
- Golding, S.E.; Valerie, K. MRE11 and ATM AKTivate pro-survival signaling. Cell Cycle 2011, 10, 3227:1–3227:5. [Google Scholar]
- Fraser, M.; Harding, S.M.; Zhao, H.; Coackley, C.; Durocher, D.; Bristow, R.G. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle 2011, 10, 2218–2232. [Google Scholar]
- Golding, S.E.; Rosenberg, E.; Valerie, N.; Hussaini, I.; Frigerio, M.; Cockcroft, X.F.; Chong, W.Y.; Hummersone, M.; Rigoreau, L.; Menear, K.A.; et al. Improved ATM kinase inhibitor ku-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther 2009, 10, 2894–2902. [Google Scholar]
- Li, Y.; Yang, D.-Q. The ATM inhibitor ku-55933 suppresses cell proliferation and induces apoptosis by blocking AKT in cancer cells with overactivated AKT. Mol. Cancer Ther 2010, 1, 113–125. [Google Scholar]
- De Bacco, F.; Luraghi, P.; Medico, E.; Reato, G.; Girolami, F.; Perera, T.; Gabriele, P.; Comoglio, P.M.; Boccaccio, C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst 2011, 103, 645–661. [Google Scholar]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar]
- Barzilai, A.; Rotman, G.; Shiloh, Y. ATM deficiency and oxidative stress: A new dimension of defective response to DNA damage. DNA Repair 2002, 1, 3–25. [Google Scholar]
- Ito, K.; Hirao, A.; Arai, F.; Matsuoka, S.; Takubo, K.; Hamaguchi, I.; Nomiyama, K.; Hosokawa, K.; Sakurada, K.; Nakagata, N.; et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004, 431, 997–1002. [Google Scholar]
- Ito, K.; Hirao, A.; Arai, F.; Takubo, K.; Matsuoka, S.; Miyamoto, K.; Ohmura, M.; Naka, K.; Hosokawa, K.; Ikeda, Y.; et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med 2006, 12, 446–451. [Google Scholar]
- Kim, J.; Wong, P.K. Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. J. Biol. Chem 2009, 284, 14396–14404. [Google Scholar]
- Guo, Z.; Deshpande, R.; Paull, T.T. ATM activation in the presence of oxidative stress. Cell Cycle 2010, 9, 4805–4811. [Google Scholar]
- Cam, H.; Easton, J.; High, A.; Houghton, P. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol. Cell 2010, 40, 509–520. [Google Scholar]
- Mongiardi, P.; Stagni, V.; Natoli, M.; Giaccari, D.; D’Agnano, I.; Falchetti, M.; Barilà, D.; Levi, A. Oxygen sensing is impaired in ATM defective cells. Cell Cycle 2011, 10, 4311–4320. [Google Scholar]
- Cosentino, C.; Grieco, D.; Costanzo, A. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011, 30, 546–555. [Google Scholar]
- Eaton, J.S.; Lin, Z.P.; Sartorelli, A.C.; Bonawitz, N.D.; Shadel, G.S. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J. Clin. Investig 2007, 117, 2723–2734. [Google Scholar]
- Ambrose, M.; Goldstine, J.V.; Gatti, R.A. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum. Mol. Genet 2007, 16, 2154–2164. [Google Scholar]
- Fu, X.; Wan, S.; Lyu, Y.L.; Liu, L.F.; Qi, H. Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. PLoS One 2008, 3, e2009. [Google Scholar]
- Luo, L.; Huang, W.; Tao, R.; Hu, N.; Xiao, Z.X.; Luo, Z. ATM and LKB1 dependent activation of ampk sensitizes cancer cells to etoposide-induced apoptosis. Cancer Lett 2013, 328, 114–119. [Google Scholar]
- Guo, Z.; Kozlov, S.; Lavin, M.F.; Person, M.D.; Paull, T.T. ATM activation by oxidative stress. Science 2010, 330, 517–521. [Google Scholar]
- Semenza, G.L. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci 2012, 33, 207–214. [Google Scholar]
- Hammond, E.M.; Dorie, M.J.; Giaccia, A.J. ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J. Biol. Chem 2003, 278, 12207–12213. [Google Scholar]
- Bencokova, Z.; Kaufmann, M.R.; Pires, I.M.; Lecane, P.S.; Giaccia, A.J.; Hammond, E.M. ATM activation and signaling under hypoxic conditions. Mol. Cell. Biol 2009, 29, 526–537. [Google Scholar]
- Ousset, M.; Bouquet, F.; Fallone, F.; Biard, D.; Dray, C.; Vlet, P.; Salles, B.; Muller, C. Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress: Role in the physiopathology of the disease. Cell Cycle 2010, 9, 2814–2822. [Google Scholar]
- Olcina, M.M.; Foskolou, I.P.; Anbalagan, S.; Senra, J.M.; Pires, I.M.; Jiang, Y.; Ryan, A.J.; Hammond, E.M. Replication stress and chromatin context link ATM activation to a role in DNA replication. Mol. Cell 2013, 52, 758–766. [Google Scholar]
- Shintani, T.; Klionsky, D.J. Autophagy in health and disease: A double-edged sword. Science 2004, 306, 990–995. [Google Scholar]
- Alexander, A.; Cai, S.-L.; Kim, J.; Nanez, A.; Sahin, M.; MacLean, K.H.; Inoki, K.; Guan, K.-L.; Shen, J.; Person, M.D.; et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl. Acad. Sci. USA 2010, 107, 4153–4158. [Google Scholar]
- Turcotte, S.; Giaccia, A.J. Targeting cancer cells through autophagy for anticancer therapy. Curr. Opin. Cell Biol 2009, 22, 1–6. [Google Scholar]
- Okuno, Y.; Nakamura-Ishizu, A.; Otsu, K.; Suda, T.; Kubota, Y. Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat. Med 2012, 18, 1208–1216. [Google Scholar]
- Allen, D.M.; van Praag, H.; Ray, J.; Weaver, Z.; Winrow, C.J.; Carter, T.A.; Braquet, R.; Harrington, E.; Ried, T.; Brown, K.D.; et al. Ataxia-telangiectasia mutated is essential during adult neurogenesis. Genes Dev 2001, 15, 554–566. [Google Scholar]
- Kim, J.; Hwangbo, J.; Wong, P.K. p38 MAPK-mediated Bmi-1 down-regulation and defective proliferation in ATM-deficient neural stem cells can be restored by AKT activation. PLoS One 2011, 6, e16615. [Google Scholar]
- Carlessi, L.; de Filippis, L.; Lecis, D.; Vescovi, A.; Delia, D. DNA-damage response, survival and differentiation in vitro of a human neural stem cell line in relation to ATM expression. Cell Deah Differ 2009, 16, 795–806. [Google Scholar]
- Maryanovich, M.; Oberkovitz, G.; Niv, H.; Vorobiyov, L.; Zaltsman, Y.; Brenner, O.; Lapidot, T.; Jung, S.; Gross, A. The ATM-bid pathway regulates quiescence and survival of haematopoietic stem cells. Nat. Cell Biol 2012, 14, 535–541. [Google Scholar]
- Bernassola, F.; Karin, M.; Ciechanover, A.; Melino, G. The HECT family of E3 ubiquitin ligases: Multiple players in cancer development. Cancer Cell 2008, 14, 10–21. [Google Scholar]
- Ruiz i Altaba, A.; Sanchez, P.; Dahmane, N. Gli and hedgehog in cancer: Tumours, embryos and stem cells. Nat. Rev. Cancer 2002, 2, 361–372. [Google Scholar]
- Di Marcotullio, L.; Ferretti, E.; Greco, A.; de Smaele, E.; Po, A.; Sico, M.A.; Alimandi, M.; Giannini, G.; Maroder, M.; Screpanti, I.; et al. Numb is a suppressor of hedgehog signalling and targets Gli1 for ITCH-dependent ubiquitination. Nat. Cell Biol 2006, 8, 1415–1423. [Google Scholar]
- Di Marcotullio, L.; Greco, A.; Mazzà, D.; Canettieri, G.; Pietrosanti, L.; Infante, P.; Coni, S.; Moretti, M.; de Smaele, E.; Ferretti, E.; et al. Numb activates the E3 ligase ITCH to control Gli1 function through a novel degradation signal. Oncogene 2011, 30, 65–76. [Google Scholar]
- Shreeram, S.; Demidov, O.N.; Hee, W.K.; Yamaguchi, H.; Onishi, N.; Kek, C.; Timofeev, O.N.; Dudgeon, C.; Fornace, A.J.; Anderson, C.W.; et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol. Cell 2006, 23, 757–764. [Google Scholar]
- Pandolfi, S.; Montagnani, V.; Penachioni, J.Y.; Vinci, M.C.; Olivito, B.; Borgognoni, L.; Stecca, B. Wip1 phosphatase modulates the hedgehog signaling by enhancing Gli1 function. Oncogene 2013, 32, 4737–4747. [Google Scholar]
- Stecca, B.; Ruiz i Altaba, A. Gli1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 2009, 28, 663–676. [Google Scholar]
- Agyeman, A.; Mazumdar, T.; Houghton, J.A. Regulation of DNA damage following termination of hedgehog (HH) survival signaling at the level of the Gli genes in human colon cancer. Oncotarget 2012, 3, 854–868. [Google Scholar]
- Hickson, I.; Zhao, Y.; Richardson, C.J.; Green, S.J.; Martin, N.M.; Orr, A.I.; Reaper, P.M.; Jackson, S.P.; Curtin, N.J.; Smith, G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004, 64, 9152–9159. [Google Scholar]
- Rainery, M.D.; Charlton, M.E.; Sytanton, R.V.; Kastan, M.B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 2008, 68, 7466–7474. [Google Scholar]
- Batey, M.A.; Zhao, Y.; Kyle, S.; Richardson, C.; Slade, A.; Martin, N.M.; Lau, A.; Newell, D.R.; Curtin, N.J. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol. Cancer Ther 2013, 12, 959–967. [Google Scholar]
- Biddlestone-Thorpe, L.; Sajjad, M.; Rosenberg, E.; Beckta, J.M.; Valerie, N.C.; Tokarz, M.; Adams, B.R.; Wagner, A.F.; Khalil, A.; Gilfor, D.; et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res 2013, 19, 3189–3200. [Google Scholar]
- Farkas, T.; Daugaard, M.; Jäättelä, M. Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy. J. Biol. Chem 2011, 286, 38904–38912. [Google Scholar]
- White, J.S.; Choi, S.; Bakkenist, C.J. Transient ATM kinase inhibition disrupts DNA damage-induced sister chromatid exchange. Sci. Signal 2010. [Google Scholar] [CrossRef]
- Choi, S.; Gamper, A.M.; White, J.S.; Bakkenist, C.J. Inhibition of ATM kinase activity does not phenocopy atm protein disruption: Implications for the clinical utility of ATM kinase inhibitors. Cell Cycle 2010, 9, 4052–4057. [Google Scholar]
- Shiloh, Y.; Ziv, Y. The ATM protein: The importance of being active. J. Cell Biol 2012, 198, 273–275. [Google Scholar]
- Jiang, H.; Reinhardt, H.C.; Bartkova, J.; Tommiska, J.; Blomqvist, C.; Nevanlinna, H.; Bartek, J.; Yaffe, M.B.; Hemann, M.T. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009, 23, 1895–1909. [Google Scholar]
- Williamson, C.T.; Kubota, E.; Hamill, J.D.; Klimowicz, A.; Ye, R.; Muzik, H.; Dean, M.; Tu, L.; Gilley, D.; Magliocco, A.M.; et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol. Med 2012, 4, 515–527. [Google Scholar]
- Gilardini Montani, M.S.; Prodosmo, A.; Stagni, V.; Merli, D.; Monteonofrio, L.; Gatti, V.; Gentileschi, M.P.; Barilà, D.; Soddu, S. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J. Exp. Clin. Cancer Res 2013, 32, 95:1–95:10. [Google Scholar]
- Peitzsch, C.; Kurth, I.; Kunz-Schughart, L.; Baumann, M.; Dubrovska, A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother. Oncol 2013, 108, 378–387. [Google Scholar]
- Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756–760. [Google Scholar]
- Raso, A.; Vecchio, D.; Cappelli, E.; Ropolo, M.; Poggi, A.; Nozza, P.; Biassoni, R.; Mascelli, S.; Capra, V.; Kalfas, F.; et al. Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia-telangiectasia mutated protein. Brain Pathol 2012, 22, 677–688. [Google Scholar]
- Yin, H.; Glass, J. The phenotypic radiation resistance of CD44+/CD24−/low breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 2011, e24080. [Google Scholar]
- Stagni, V.; Santini, S.; Barilà, D. A new player in the development of TRAIL based therapies for hepatocarcinoma treatment: ATM kinase. Cancers 2012, 4, 354–378. [Google Scholar]
© 2014 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Stagni, V.; Oropallo, V.; Fianco, G.; Antonelli, M.; Cinà, I.; Barilà, D. Tug of War between Survival and Death: Exploring ATM Function in Cancer. Int. J. Mol. Sci. 2014, 15, 5388-5409. https://doi.org/10.3390/ijms15045388
Stagni V, Oropallo V, Fianco G, Antonelli M, Cinà I, Barilà D. Tug of War between Survival and Death: Exploring ATM Function in Cancer. International Journal of Molecular Sciences. 2014; 15(4):5388-5409. https://doi.org/10.3390/ijms15045388
Chicago/Turabian StyleStagni, Venturina, Veronica Oropallo, Giulia Fianco, Martina Antonelli, Irene Cinà, and Daniela Barilà. 2014. "Tug of War between Survival and Death: Exploring ATM Function in Cancer" International Journal of Molecular Sciences 15, no. 4: 5388-5409. https://doi.org/10.3390/ijms15045388